Biological Significance of the Bloom's Syndrome Protein

Since 1960, persons with the very rare disorder Bloom's syndrome (BS) have been followed clinically, documenting clinical matters as obtained from their doctors. This has been a worldwide search for cases, though a few in the New York City area are seen (personally, by us) perhaps once every 2-3 years. BS is a rare genetically-determined disorder described in NYC in 1954. The clinical courses of the 169 persons diagnosed BS by 1991 are followed in a program referred to as the Bloom's Syndrome Registry. BS is the prototype of the "chromosome-breakage syndromes." BS cells mutate at a greater rate than any other, and the consequence is the greatest known predisposition to cancers of the types that affect the general human population. We are defining the clinical syndrome and at the same time are studying cells from affected families in the experimental laboratory. BS is a model for learning about cancer. Our contact with families lets us know of cancers arising, but blood, and sometimes tiny biopsies of skin, is taken if available so that (a) the chromosomes can be studied and (b) the gene mutations can be defined in molecular terms.

Study Overview

• Status: Completed
• Conditions: Bloom Syndrome

Detailed Description

Although an occasional person with BS will be admitted to the hospital for special study (endocrine evaluation mainly)--two in the last 25 years--the Registry does not develop a doctor/patient relationship with affected persons. They have their own doctors. We gather information about the affected persons and publish reports. We also publish reports of experiments carried out in the research laboratory using BS cells. Because we are a central repository for information on BS, families or their physicians find contact with us beneficial, and we provide them with information requested. Sometimes pregnancies at risk occur, and we have on occasion made cytogenic (chromosome) analysis of cultured cells of amniotic fluid (the cultures being initiated elsewhere and sent to us for cytogenetic study).

Although the accessioning of new cases to the Registry was closed in 1991, 4-5 new patients are referred to us each year, and their clinical courses also are being followed. To date, the 169 officially registered and 36 additional cases are under our surveillance.

• Study Type: Observational

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10021
      • New York Hospital-Cornell Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 55 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

1. families include those ascertained by physician referral and those families already accessioned to The Bloom's Syndrome Registry
2. the family has at least one affected member with BS

Study Plan

How is the study designed?

Design Details

• Observational Models: Defined Population
• Time Perspectives: Other

Collaborators and Investigators

• Sponsor: National Center for Research Resources (NCRR)

Study record dates

Study Registration Dates

• First Submitted: July 11, 2001
• First Submitted That Met QC Criteria: July 12, 2001
• First Posted (Estimate): July 13, 2001

Study Record Updates

• Last Update Posted (Estimate): June 24, 2005
• Last Update Submitted That Met QC Criteria: June 23, 2005
• Last Verified: December 1, 2003

More Information

Terms related to this study

• Keywords: Bloom syndrome protein
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Disease; Congenital Abnormalities; Genetic Diseases, Inborn; DNA Repair-Deficiency Disorders; Abnormalities, Multiple; Primary Immunodeficiency Diseases; Syndrome; Bloom Syndrome
• Other Study ID Numbers: NCRR-M01RR06020-0060